Site search

Clear filter
2893 results for '' found
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)
/
A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)
/
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
/
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
/
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Par
/
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
/
PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)
/
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants
/
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared
/
Patient Reported Outcomes in patients received DVd for relapsed MM (ACTRN12618000659202)
Patient Reported Outcomes in patients received DVd for relapsed MM (ACTRN12618000659202)
/
26 27 28 29 30